BIA

Generic Name: BIA

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₀F_₃N_₃O_₅

Unique Ingredient Identifier: X6H65DT067

Clinical Trials

Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: BIA 2-093

First Posted Date: 2014-11-06

Last Posted Date: 2014-12-10

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 26

Registration Number: NCT02284828

Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: BIA 2-093
Drug: Carbamazepine

First Posted Date: 2014-11-06

Last Posted Date: 2015-01-08

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 43

Registration Number: NCT02284854

Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: BIA 2-093
Drug: Phenytoin

First Posted Date: 2014-11-05

Last Posted Date: 2014-12-18

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 32

Registration Number: NCT02283827

Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: BIA 2-093

First Posted Date: 2014-11-05

Last Posted Date: 2014-12-10

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 60

Registration Number: NCT02283840

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: BIA 2-093
Drug: Moxifloxacin
Drug: Placebo

First Posted Date: 2014-11-05

Last Posted Date: 2025-04-11

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 67

Registration Number: NCT02283788

Locations: 🇺🇸
Comprehensive Phase OneTM, Miramar, Florida, United States

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: BIA 2-093
Drug: Topamax

First Posted Date: 2014-11-05

Last Posted Date: 2025-04-11

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 32

Registration Number: NCT02283814

An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: BIA 2-093

First Posted Date: 2014-11-02

Last Posted Date: 2014-12-31

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 40

Registration Number: NCT02281422

Locations: 🇿🇦
Farmovs-Parexel, Bloemfontein, South Africa

Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: BIA 2-093
Drug: Contraceptives, Oral, Combined

First Posted Date: 2014-11-02

Last Posted Date: 2014-12-03

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 20

Registration Number: NCT02281448

Locations: 🇵🇹
BIAL - Portela & Cª, S.A., S. Mamede do Coronado, Portugal

Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: BIA 2-093
Drug: S-licarbazepine
Drug: R-licarbazepine

First Posted Date: 2014-11-02

Last Posted Date: 2025-04-08

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 32

Registration Number: NCT02281591

Locations: 🇩🇪
Scope International Life Sciences AG,, Hamburg, Germany

An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: BIA 2-093

First Posted Date: 2014-11-02

Last Posted Date: 2015-01-12

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 17

Registration Number: NCT02281526

Locations: 🇿🇦
Farmovs-Parexel, Bloemfontein, South Africa

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy